EcoR1 Capital

EcoR1 Capital invests exclusively in biotechnology companies, spanning early-stage seed rounds, startup financings, and later-stage expansion or crossover opportunities. The firm evaluates opportunities against a framework it calls "four-dimensional" — weighing scientific data, clinical trial timelines, financial structure, and market dynamics. Its portfolio draws from platform technologies and therapeutic programs without sector diversification into non-life sciences verticals.

EcoR1 Capital does not publicly name its founder, managing partners, or investment committee members on its website or in available public filings as of the most recent Altss review. The firm operates without publicly disclosed bios or governance structure. This absence of named principals creates an information gap for allocators conducting operational due diligence.

EcoR1 Capital's disclosed approach includes venture-stage and late-stage biotech investments, with materials referencing both private and crossover exposure. The firm's posture as a "patient-driven" investor suggests willingness to hold positions across the private-to-public transition when the underlying science merits a longer time horizon, though specific public-equity positions are not enumerated.

EcoR1 Capital does not publicly report assets under management, fund size, or historical returns. Its website and public materials avoid quantitative disclosures about fund performance, vintage-year returns, or total capital deployed since inception. Allocators will need to obtain this data directly from the firm through a formal due-diligence process.

EcoR1 Capital does not publicly describe its co-investment policy or syndication practices. The firm's website emphasizes proprietary sourcing and internal scientific conviction, without referencing co-investor clubs, institutional limited partners, or sidecar vehicles. Direct inquiry to the firm would be required to confirm current co-investment posture.